PCM
ABEO icon

Prelude Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Prelude Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-216
Closed -$22K – 1423
2015
Q3 		$22K Buy
+216
New +$28.7K ﹤0.01% 1234

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's ABEO Position: Q2 2026 in Review

Prelude Capital Management reduced its Abeona Therapeutics (ABEO) stake by 40% in Q2 2026, selling an estimated $204K and leaving 55,938 shares worth $346K. The position accounts for 0.03% of the portfolio, ranked #693.

Prelude Capital Management first reported a position in ABEO in Q2 2015 and has held it in 23 quarters since. The position peaked at $586K in Q4 2025. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Prelude Capital Management held 55,938 shares of Abeona Therapeutics worth $346K as of Q2 2026.
  • Prelude Capital Management sold 37,135 Abeona Therapeutics shares in Q2 2026, an estimated $204K.
  • Abeona Therapeutics made up 0.03% of Prelude Capital Management's portfolio in Q2 2026, its #693 holding.
  • Prelude Capital Management first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 23 quarters since.
  • Prelude Capital Management's Abeona Therapeutics position peaked at $586K in Q4 2025.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.